Source:http://linkedlifedata.com/resource/pubmed/id/15376307
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
10
|
pubmed:dateCreated |
2004-9-22
|
pubmed:abstractText |
Liver transplantation (LT) in human immunodeficiency virus (HIV)-positive individuals is considered to be an experimental therapy with limited reported worldwide experience, and little long-term survival data. Published data suggest that the short-term outcome is encouraging in selected patients. Here, we report our experience in 14 HIV-infected liver allograft recipients, and compare outcomes between those coinfected with hepatitis C virus (HCV) and the non-HCV group. A total of 14 HIV-infected patients (12 male, 2 female, age range 26-59 years) underwent LT between January 1995 and April 2003. Indications for LT were HCV (n = 7), hepatitis B virus (HBV; n = 4), alcohol-induced liver disease (n = 2), and seronegative hepatitis (n = 1); 3 patients presented with acute liver failure. At LT, CD4 cell counts (T-helper cells that are targets for HIV) ranged from 124 to 500 cells/microL (mean 264), and HIV viral loads from <50 to 197,000 copies/mL. Nine of 12 patients were exposed to highly active antiretroviral therapy (HAART) before LT. In the non-HCV group (n = 7), all patients are alive, all surviving more than 365 days (range 668-2,661 days). No patient has experienced HBV recurrence, and graft function is normal in all 7 patients. However, 5 of 7 HCV-infected patients died after LT at 95-784 days (median 161 days). A total of 4 patients died of complications due to recurrent HCV infection and sepsis, despite antiviral therapy in 3 of them. A total of 3 patients experienced complications relating to HAART therapy. In conclusion, outcome of LT in HIV-infected patients with HBV or other causes of chronic liver disease indicates that LT is an acceptable therapeutic option in selected patients. However, longer follow-up in larger series is required before a conclusive directive can be provided for HCV / HIV coinfected patients requiring LT.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:status |
MEDLINE
|
pubmed:month |
Oct
|
pubmed:issn |
1527-6465
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
1271-8
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15376307-Adult,
pubmed-meshheading:15376307-Antiretroviral Therapy, Highly Active,
pubmed-meshheading:15376307-Female,
pubmed-meshheading:15376307-HIV Infections,
pubmed-meshheading:15376307-Hepatitis B,
pubmed-meshheading:15376307-Hepatitis C,
pubmed-meshheading:15376307-Humans,
pubmed-meshheading:15376307-Liver Cirrhosis, Alcoholic,
pubmed-meshheading:15376307-Liver Failure, Acute,
pubmed-meshheading:15376307-Liver Transplantation,
pubmed-meshheading:15376307-Male,
pubmed-meshheading:15376307-Middle Aged,
pubmed-meshheading:15376307-Retrospective Studies,
pubmed-meshheading:15376307-Survival Analysis,
pubmed-meshheading:15376307-Treatment Outcome
|
pubmed:year |
2004
|
pubmed:articleTitle |
Outcomes of liver transplantation in HIV-infected individuals: the impact of HCV and HBV infection.
|
pubmed:affiliation |
Institute of Liver Studies, King's College Hospital, London, UK. snorris@stjames.ie
|
pubmed:publicationType |
Journal Article,
Comparative Study
|